Edasalonexent MoveDMD Trial Results 2017

Presentation of top-line results from Part B of the MoveDMD trial evaluating edasalonexent, an oral NF-κB inhibitor, in young boys with Duchenne muscular dystrophy. The Phase 1/2 trial assessed safety, efficacy, and functional outcomes using MRI imaging and timed function tests.